Clinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus

dc.contributor.authorPavlikova, Ksenia
dc.contributor.authorLiadova, Tetiana
dc.contributor.authorVolobuieva, Olga
dc.contributor.authorGololobova, Olesya
dc.contributor.authorVinnikova, Nataliia
dc.date.accessioned2025-04-10T09:13:27Z
dc.date.issued2021
dc.descriptionThe aim of the study was to evaluate the effectiveness of the drug Nuclex (ribonucleic acid) in the correction of immune disorders in patients with IM caused by EBV. The combination therapy including Nuclex and valacyclovir leads to a reduction in the duration of clinical symptoms among patients with IM compared with valacyclovir use only. Addition of Nuclex to antiviral therapy with valacyclovir improves immunogram parameters in patients with IM more effectively compared with valacyclovir use only.
dc.description.abstractThe study of the role of Epstein-Barr virus (EBV) infection in the occurrence of various pathological human conditions is of great importance. This is due to the significant epidemiological role and social significance, as according to epidemiological data more than 90 % of people are already infected with EBV when they reach adulthood. The steady increase in the number of diseases caused by EBV in both adults and children, due to its specific tropism to immunocompetent cells, lifelong persistence, and latent course, necessitates a comprehensive study and development of effective treatment methods. Therefore, it is very important to conduct research to find effective treatment regimens that aim to rehabilitate the immune system, promote the regression of immune changes and complications and prevent recurrence in various forms of EBV infection.
dc.identifier.citationPavlikova, Ksenia. Clinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus / K. Pavlikova, T. Liadova, O. Volobueva, O. Gololobova, N. Vinnikova // EUREKA: Health Sciences. – 2021. – No. 6. – P. 3–9. – DOI: http://doi.org/10.21303/2504-5679.2021.002177
dc.identifier.doihttp://doi.org/10.21303/2504-5679.2021.002177
dc.identifier.orcid0000-0002-1228-4915
dc.identifier.orcid0000-0002-5892-2599
dc.identifier.orcid0000-0002-5569-1748
dc.identifier.orcid0000-0002-1111-2302
dc.identifier.orcid0000-0003-2598-4264
dc.identifier.urihttps://ekhnuir.karazin.ua/handle/123456789/21068
dc.language.isoen
dc.publisherTallinn : Scientific Route OÜ®
dc.subjectMEDICINE
dc.subjectinfectious mononucleosis
dc.subjectEpstein-Barr virus
dc.subjectimmune response
dc.subjectantiviral and immunomodulatory therapy
dc.titleClinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus
dc.typeArticle

Файли

Контейнер файлів

Зараз показуємо 1 - 2 з 2
Вантажиться...
Ескіз
Назва:
Договор Волобуєва Eureka,21.doc
Розмір:
434 KB
Формат:
Microsoft Word
Вантажиться...
Ескіз
Назва:
Clinical and immunological efficiency (Scopus).pdf
Розмір:
89.84 KB
Формат:
Adobe Portable Document Format

Ліцензійна угода

Зараз показуємо 1 - 1 з 1
Вантажиться...
Ескіз
Назва:
license.txt
Розмір:
8.3 KB
Формат:
Item-specific license agreed upon to submission
Опис: